24.69 USD
▲+0.01+6.33%
盘后 23.20 -0.09%
2026-08-03
市值
$2.56B
市盈率
—
EPS
-3.41
股息率
—
52 周区间
8.20 – 25.09
成交量
1.19M
Beta
1.80
目标价
33.13
52W 低 8.2052W 高 25.09
价格走势
公司简介
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical tr...